Document is current
Any future updates will be listed below
-
Authors
Talavera Andújar, Begoña https://orcid.org/0000-0002-3430-9255
Aurich, Dagny https://orcid.org/0000-0001-8823-0596
Aho, Velma T. E. https://orcid.org/0000-0003-2916-7018
Singh, Randolph R. https://orcid.org/0000-0003-4500-3400
Cheng, Tiejun https://orcid.org/0000-0002-4486-3356
Zaslavsky, Leonid https://orcid.org/0000-0001-5873-4873
Bolton, Evan E. https://orcid.org/0000-0002-5959-6190
Mollenhauer, Brit
Wilmes, Paul https://orcid.org/0000-0002-6478-2924
Schymanski, Emma L. https://orcid.org/0000-0001-6868-8145
-
Funding
Funding for this research was provided by:
European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 863664)
National Center for Biotechnology Information of the National Library of Medicine
Parkinson’s Foundation (MiBiPa Saliva)
Michael J. Fox Foundation for Parkinson's Research (14701 (MiBiPa-PLUS))
Michael J. Fox Foundation for Parkinson's Research (MJFF-019228 (PARKdiet))
“Microbiomes in One Health” PhD training program
Luxembourg National Research Fund (FNR; CORE/16/BM/11333923)
Luxembourg National Research Fund (MiBiPa)
Luxembourg National Research Fund (Project A18/BM/12341006)
- License Information
-
More Information
Article History
Received: 8 April 2022
Revised: 14 June 2022
Accepted: 28 June 2022
First Online: 13 July 2022
Declarations
:
: The collection of plasma and fecal samples was part of the DeNoPa cohort, conducted according to the Declaration of Helsinki. Subjects were recruited in Paracelsus-Elena Klinik, Kassel (Germany). Written informed consent was obtained from all study participants. The study was registered at the German Register for Clinical trials (DRKS00000540) and approved by the Comite National d’Ethique de Recherche of Luxembourg (Reference No.: 140174_ND). Subjects that served as controls were healthy, free of PD, or without PD symptoms, more details can be found in previous publications [, ].
: The authors declare no competing interests.
